Elagolix and Estradiol and Norethindrone
Brand names: Oriahnn · Active ingredient: Elagolix Sodium, Norethindrone, Estradiol
In short: ORIAHNN is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. Limitation of Use: Use of ORIAHNN should be limited to 24 months due to the risk of continued bone loss, which may not be reversible .
What is Elagolix and Estradiol and Norethindrone used for?
ORIAHNN is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
Limitation of Use:
Use of ORIAHNN should be limited to 24 months due to the risk of continued bone loss, which may not be reversible .
âš Boxed warning (FDA's strongest warning)
Estrogen and progestin combinations, including ORIAHNN, increase the risk of thrombotic or thromboembolic disorders including pulmonary embolism, deep vein thrombosis, stroke and myocardial infarction, especially in women at increased risk for these events
.
ORIAHNN is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and in women at increased risk for these events, including women over 35 years of age who smoke and women with uncontrolled hypertension
.
Elagolix and Estradiol and Norethindrone dosage
Exclude pregnancy before starting ORIAHNN or start ORIAHNN within 7 days from the onset of menses .
The recommended dosage of ORIAHNN is:â—‹ One elagolix 300 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg capsule in the morning (AM), andâ—‹ One elagolix 300 mg capsule in the evening (PM).
Take the morning and evening capsules at approximately the same time each day, with or without food.
The recommended duration of treatment with ORIAHNN is 24 months .
Instruct the patient to take the missed dose of ORIAHNN within 4 hours of the time that it was supposed to be taken and then the next dose at the usual time. If more than 4 hours have passed since a capsule is usually taken, instruct the patient not to take the missed dose and take the next dose at the usual time. Take only one morning capsule and one evening capsule per day.
How to take Elagolix and Estradiol and Norethindrone — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Thromboembolic Disorders and Vascular Events
Advise patients that use of estrogen and progestin combinations may increase the risk of thromboembolic disorders and vascular events, especially in women at high risk for these events [see
Boxed Warning
, Contraindications
(
4
)
, Warnings and Precautions
(
5.1
)
, and Adverse Reactions
(
6.1
)
].
Bone Loss
Advise patients about the risk of bone loss. Advise patients that supplementary calcium and vitamin D may be beneficial if dietary intake of calcium and vitamin D is not adequate. Advise patients that oral iron supplement should not be taken at the same time as calcium and vitamin D .
Suicidal Ideation and Exacerbation of Mood Disorders
Advise patients that suicidal ideation and exacerbation of mood disorders may occur with ORIAHNN use. Instruct patients with new onset or worsening depression, anxiety, or other mood changes to promptly seek medical attention .
Liver Injury
Advise patients to promptly seek medical attention in case of signs or symptoms that may reflect liver injury, such as jaundice . …
Warnings & precautions
Do not take this medicine if: ORIAHNN is contraindicated in women:
With a high risk of arterial, venous thrombotic, or thromboembolic disorders . Examples include women over 35 years of age who smoke, and women who are known to have:â—‹ current or history of deep vein thrombosis or pulmonary embolismâ—‹ vascular disease (e.g., cerebrovascular disease, coronary artery disease, peripheral vascular disease)â—‹ thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) â—‹ inherited or acquired hypercoagulopathiesâ—‹ uncontrolled hypertensionâ—‹ headaches with focal neurological symptoms or have migraine headaches with aura if over age 35
Who are pregnant. Exposure to ORIAHNN early in pregnancy may increase the risk of early pregnancy loss .
With known osteoporosis because of the risk of further bone loss .
With current or history of breast cancer or other hormonally-sensitive malignancies, and with increased risk for hormonally-sensitive malignancies .
With known hepatic impairment or disease .
With undiagnosed abnormal uterine bleeding.
With known anaphylactic reaction, angioedema, or hypersensitivity to ORIAHNN or any of its components.
Taking inhibitors of organic anion transporting polypeptide (OATP)1B1 (a hepatic uptake transporter) that are known or expected to significantly increase elagolix plasma concentrations .
ORIAHNN is contraindicated in women with current or history of thrombotic or thromboembolic disorders and in women at increased risk for these events . In the Phase 3 clinical trials (Studies UF-1, UF-2, and UF-3), two thrombotic events occurred in 453 ORIAHNN-treated women (thrombosis in the calf and pulmonary embolism) . …
Elagolix and Estradiol and Norethindrone side effects
The following serious adverse reactions are discussed elsewhere in labeling:
Thromboembolic Disorders and Vascular Events
Bone Loss
Suicidal Ideation, Suicidal Behavior, and Exacerbation of Mood Disorders
Hepatic Transaminase Elevations
Elevated Blood Pressure
Effects on Carbohydrate and Lipid Metabolism
Alopecia
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of ORIAHNN was evaluated in two 6-month, randomized, double-blind, placebo-controlled trials (Studies UF-1 and UF-2), in which 790 premenopausal women received at least 1 dose of ORIAHNN (n=395), elagolix 300 mg twice daily (n=199), or placebo (n=196) . Women who completed 6-month treatment in either Study UF-1 or Study UF-2 and met eligibility criteria (n=433) entered a 6-month extension study (Study UF-3), receiving either ORIAHNN (n=276) or elagolix 300 mg twice daily (n=157). Elagolix 300 mg twice daily is not an approved dosage but was included as a reference arm. A total of 341 women received ORIAHNN for 6 months and 182 women received ORIAHNN for 12 months.
Serious Adverse Events
Serious adverse events were reported in three (0.8%) ORIAHNN-treated women in Studies UF-1 and UF-2. …
Drug interactions
Elagolix (a component of ORIAHNN) is:
A weak to moderate inducer of cytochrome P450 (CYP3A). Co-administration with ORIAHNN may decrease plasma concentrations of drugs that are substrates of CYP3A.
A weak inhibitor of CYP2C19. Co-administration with ORIAHNN may increase plasma concentrations of drugs that are substrates of CYP2C19 .
An inhibitor of efflux transporter P-glycoprotein (P-gp). Co-administration with ORIAHNN may increase plasma concentrations of drugs that are substrates of P-gp .
The effects of co-administration of ORIAHNN on concentrations of concomitant drugs and the clinical recommendations for these drug interactions are summarized in Table 3.
Concomitant
Drug Class:
Drug Name | Effect on
Plasma
Exposure of
Concomitant
Drug | Clinical Recommendations
Cardiac glycosides:digoxin | ↑ digoxin | Increase monitoring of digoxin concentrations and potential signs and symptoms of clinical toxicity when initiating ORIAHNN in patients who are taking digoxin. If ORIAHNN is discontinued, increase monitoring of digoxin concentrations.
Benzodiazepines:oral midazolam | ↓ midazolam | Consider increasing the dose of midazolam by no more than 2-fold and individualize midazolam therapy based on the patient’s response. …
About this medicine
ORIAHNN consists of two capsules: one to be taken orally in the morning (AM) and one to be taken orally in the evening (PM). The AM capsule is white and yellow and contains 300 mg elagolix (equivalent to 310.4 mg of elagolix sodium), 1 mg estradiol, and 0.5 mg norethindrone acetate. The PM capsule is white and light blue and contains 300 mg of elagolix (equivalent to 310 mg of elagolix sodium).
Elagolix
Elagolix sodium is the sodium salt of the active moiety elagolix, a nonpeptide small molecule, GnRH receptor antagonist. Elagolix sodium is chemically described as sodium 4-({(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino)butanoate. Elagolix sodium has a molecular formula of C32H29F5N3O5Na and a molecular weight of 653.58. Elagolix free acid has a molecular formula of C32H30F5N3O5 and a molecular weight of 631.60.
Elagolix sodium has the following structural formula:
Elagolix sodium is a white to off-white to light yellow powder and is freely soluble in water. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 99f6eee7-7e52-6999-7eb8-488d06dd1710. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone